Walgreens is expanding its specialty pharmacy services to focus on cell and gene therapies, which are becoming increasingly prevalent in the treatment of chronic diseases. The company is launching a new business unit dedicated to specialty pharmacy, including its subsidiary AllianceRx, which will fall under its core U.S. retail pharmacy division. Walgreens is also opening a new facility in Pittsburgh dedicated to services for cell and gene therapies, as part of its efforts to transform its specialty pharmacy services. This move comes in response to the surge in approvals of cell and gene therapies in the U.S. and European Union, and the expectation that the market will continue to grow.
